Objective: To describe patterns of antibiotic recommendations by office-based physicians from five regions in Canada between 2007 and 2011.
Introduction
The Canadian Integrated Program for Antimicrobial Resistance Surveillance (CIPARS) monitors trends in antimicrobial use and antimicrobial resistance in selected bacterial organisms from human, animal and food sources across Canada. The Program is based on several representative and methodologically unified surveillance components that can be linked to examine the relationship between antimicrobials used in food animals and humans, and the associated health impacts. This information supports: (i) the creation of evidence-based policies to control antimicrobial use in hospital, community, and agricultural settings, and thus prolong the effectiveness of these drugs; and (ii) the identification of appropriate measures to contain the emergence and spread of resistant bacteria between animals, food, and people in Canada. The human antimicrobial use surveillance reports are published on a regular basis to provide a national overview of current antimicrobial use practices in Canada annually, to enable comparisons and to support formulary and stewardship development. The objective of this paper is to summarize the most recent CIPARS report that describes patterns of antibiotic recommendations by office-based physicians from five regions in Canada between 2007 and 2011 (1) .
Methods
The Canadian Disease and Therapeutic Index (CDTI) dataset is purchased by the Public Health Agency of Canada from IMS Health Canada Inc. This dataset provides information about the patterns and treatments of disease encountered by office-based physicians from five regions: Atlantic (New Brunswick, Newfoundland and Labrador, Nova Scotia, and Prince Edward Island), Québec, Ontario, the Prairies (Alberta, Manitoba, and Saskatchewan), and British Columbia. Values are estimated based on quarterly data from a sample of approximately 652 physicians stratified by region and specialty. For four consecutive quarters, each physician maintains a practice diary describing information on every patient visit during a randomly selected 48-hour period. This information is then extrapolated using a projection factor to estimate the "universe" comprised of approximately 52,959 physicians, roughly representing all Canadian data.
The information contained in this analysis is for antimicrobials for which a physician has provided a recommendation or prescription, and does not represent actual prescriptions dispensed by pharmacists or consumed by the patient. This data does not include patient visits to a primary care nurse, and diagnosis visits do not translate into the total number of patients, as some patients visited multiple times for the same reason or were diagnosed with multiple diseases. Due to the methods of data collection, sample size is sometimes considered too small for decision making. However, information is still included in this analysis to provide a view of practices which may require further study.
Results
Over the five-year surveillance period (2007−2011) physicians saw patients for almost 1.5 billion diagnoses and provided a total of approximately 121 million antimicrobial recommendations (1) . In 2011, a total of 289 million clinical diagnoses were made of which 8% resulted in an antimicrobial recommendation ( Table 1) . During that year, out of all the antimicrobials recommended by office-based physicians, 51.3% were for treatment of diseases of the respiratory system followed by infections of the urinary tract (14.5%) and diseases of the skin and subcutaneous tissue (11.3%) Antimicrobials were recommended to all age groups in 2011, with proportionally higher recommendation rates to patients in the age group 0−2 years (12 antimicrobial recommendations per 10 inhabitants); 3−9 years (9 antimicrobial recommendations per 10 inhabitants); and 60−64 years, and 65 years of age or older (7 antimicrobial recommendations per 10 inhabitants for each age group) ( The most commonly recommended antimicrobials in 2011 were the macrolides (1,638 recommendations per 10,000 inhabitants), penicillins with extended spectrum (1,504 recommendations per 10,000 inhabitants), and the fluoroquinolones (1,202 recommendations per 10,000 inhabitants). However, high increases in the number of physician recommendations were observed for third generation cephalosporins (a 42% increase compared to 2007) due to an increase in recommendations for treatment of diseases of the respiratory system, diseases of the genitourinary system, and infections of the urinary tract.
Provincial variation in the total number of antimicrobial recommendations per 10,000 inhabitants was observed, with the Atlantic region (7,101 recommendations per 10,000 inhabitants) and Québec (8,268 recommendations per 10,000 inhabitants) having the highest rates compared to the overall national level. Rates of diagnoses and antimicrobial recommendations per 10,000 inhabitants varied depending upon the province and disease of treatment. Provincial preferences for antimicrobial of choice for treatment of disease were also observed ( Table 3) . 4 The Prairies include the provinces of Alberta, Saskatchewan, and Manitoba. 5 The Atlantic region includes the provinces of New Brunswick, Nova Scotia, Prince Edward Island, and Newfoundland and Labrador. .3 ¹Diagnosis does not represent the number of times a person visits, but represents every time a diagnosis is provided; if a person presents with multiple diseases each individual disease/diagnosis is recorded separately. ²Data does not represent actual prescriptions dispensed by pharmacists or products consumed by the patient, as information on patient compliance was not available. ³NAS = no antimicrobials suggested (recommended). 4 The Prairies include the provinces of Alberta, Saskatchewan, and Manitoba. 5 The Atlantic region includes the provinces of New Brunswick, Nova Scotia, Prince Edward Island, and Newfoundland and Labrador. 4 The Prairies include the provinces of Alberta, Saskatchewan, and Manitoba. 5 The Atlantic region includes the provinces of New Brunswick, Nova Scotia, Prince Edward Island, and Newfoundland and Labrador.
Discussion
Eight percent of clinical diagnoses provided by office-based physicians resulted in an antimicrobial being recommended in 2011. Of these, 51% were for the treatment of diseases of the respiratory system, followed by 14% for infections of the urinary tract, and 11% for diseases of skin and subcutaneous tissue. Antimicrobial recommendations were highest for patients in the age groups of 0−2 years, 3−9 years, and 65 years or older. Antimicrobial recommendation rates decreased between 2007 and 2011 for diseases of the ear, the respiratory system, infections of the urinary tract, and diseases of the skin and subcutaneous tissue, while the rates for diseases of the genitourinary system remained stable.
Overall, the most commonly recommended antimicrobials included macrolides, penicillins with extended spectrum and fluoroquinolones. Provincial differences were observed in the antimicrobial recommendation rates and antimicrobial selected for treatment, with the Atlantic region and Québec having higher rates of antimicrobial recommendations compared to the national levels. British Columbia had the lowest rate of antimicrobial recommendations for diseases of the respiratory system, while Québec and the Atlantic region had the highest for diseases of the ear. The Prairies had the lowest rate of antimicrobial recommendations for infections of the urinary tract, but did observe an increase in these between 2010 and 2011. A similar rate of antimicrobial recommendations across the country was observed for diseases of the genitourinary system, while decreases in recommendations were observed across the country for diseases of the skin and subcutaneous tissue.
There are several limitations and caveats within the CDTI dataset. The drugs listed are those that the physician has written or recommended and do not represent actual prescriptions dispensed by pharmacists or products consumed by the patient, as information on patient compliance was not available. The data do not include patient visits to a primary care nurse, and diagnosis visits do not translate into number of patients as some patients may have visited multiple times for the same reason or were diagnosed with multiple diseases.
The appearance of a drug may include samples that do not necessarily tie to a prescription dispensed as physicians list all suggested treatments. Physicians also record drugs "previously ordered and continued" for the diagnosis, which would not necessarily tie to a prescription dispensed. In addition, some drug therapy and diagnosis is under-represented due to self-medication (i.e., over-the-counter products). Sample size is sometimes considered too small for decision making; however, these have been included for information purposes only and reliability of the data is dependent on sampling error, so caution should be taken when interpreting those disease categories with a small sample size. Data are only available at the regional level, where fluctuations may be more or less obvious and specific information for individual provinces could not be determined. Antimicrobial resistance will continue to challenge the health of Canadians and those around the world for some time to come. Antibiotic use surveillance will help document the progress we have made in curbing it and the impact these changes might have had on overall antibiotic resistance.
